Bayer Just Found a Way to Photograph Your Heart's Worst Secret

What Evuzamitide Actually Does

Think of evuzamitide as a molecular flashlight. It's built from a synthetic peptide called p5+14, a 45-amino-acid chain studded with positively charged building blocks (lysines). When injected into the bloodstream, these charged regions are electrostatically attracted to amyloid deposits the way a magnet sticks to a refrigerator door. The peptide doesn't care which type of amyloid protein caused the buildup; it's a pan-amyloid tracer, meaning it binds to deposits from both major cardiac subtypes (ATTR and AL).

The iodine-124 label is the "flashlight" part. Once the peptide locks onto amyloid in the heart, the radioactive iodine emits a signal that a PET/CT scanner can detect and image. One injection, one scan, one answer.

That pan-amyloid quality matters. Current bone tracer scans are mainly useful for ATTR amyloidosis. If you have AL amyloidosis (caused by abnormal antibody fragments), the bone scan might miss it or mislead your doctor. A tracer that catches both subtypes in the same test could simplify a notoriously confusing diagnostic workup.

Inside the REVEAL Numbers

The REVEAL trial was a multicenter, open-label study across 19 U.S. sites enrolling 170 adults with suspected cardiac amyloidosis. Patients got the PET scan, and three independent readers evaluated the images without knowing the clinical diagnosis. Those reads were then compared against an expert-adjudicated reference diagnosis using the full standard-of-care workup.

The headline result: a majority read delivered 94% sensitivity and 86% specificity. When you break it down by individual reader, sensitivity came in at 94%, 94%, and 90% across the three reviewers. That kind of consistency matters because a diagnostic test is only useful if different doctors reading the same scan reach similar conclusions.

Safety looked clean too. Among the 170 participants, Bayer reported no deaths and no discontinuations related to evuzamitide during the study period. For a diagnostic agent, that's essentially the minimum bar you need to clear, but it's reassuring nonetheless.

Bayer also presented secondary analyses breaking down performance in ATTR versus AL amyloidosis, though the detailed subgroup numbers will be critical for understanding exactly where this test adds the most value over existing options.

The $10 Billion Question Nobody's Asking

Here's why this diagnostic story is actually a commercial story. The cardiac amyloidosis drug market is heating up fast. Pfizer's tafamidis still dominates with an estimated 75–78% share of treated patients, but BridgeBio's acoramidis (approved late 2024) and Alnylam's vutrisiran (approved for ATTR-CM in 2025) are fighting for the same patients.

The catch? You can't treat patients you haven't found. The market isn't supply-constrained; it's diagnosis-constrained. Every pharma company selling an ATTR drug has the same problem: the pool of identified patients is a fraction of the people who actually have the disease. A better diagnostic doesn't just help patients. It unlocks revenue for every company in the space by expanding the treatable population.

That's why Bayer's move is strategic, not just scientific. The company acquired evuzamitide (originally called AT-01) from Attralus in January 2026 as part of a broader push into molecular imaging. The tracer already had FDA Breakthrough Therapy Designation and Orphan Drug Designation in both the U.S. and EU before Bayer took it over. By pairing a diagnostic tracer with its existing cardiovascular pipeline, Bayer is positioning itself at the front door of the entire cardiac amyloidosis treatment funnel.

What Still Needs to Happen

Promising Phase 3 data is not the same as an approved product. The full ESC presentation and peer review will need to confirm the numbers, and regulators will want to see that the test changes clinical decisions, not just diagnostic labels. Key open questions include how well the tracer distinguishes ATTR from AL in ambiguous cases, whether results are reproducible across different PET centers, and what the test will cost relative to existing options.

There's also a practical consideration: PET scanners aren't everywhere. Bone scintigraphy is cheaper and more widely available. Evuzamitide will need to prove it offers enough incremental value to justify the infrastructure requirements.

But if it does? A single, noninvasive scan that catches both types of cardiac amyloidosis could reshape how cardiologists think about unexplained heart failure. And for the companies selling expensive amyloidosis drugs, it could be the diagnostic key that finally opens a much bigger market.

Sometimes the biggest breakthrough isn't a new treatment. It's figuring out who needs one.

The First Pill for a Disease That Eats Your Muscles and Skin

The FDA just approved the first-ever targeted pill for dermatomyositis, a rare autoimmune disease that attacks muscles and skin. Roivant's factory-style drug development model notched another win, but Wall Street wants to see receipts before celebrating.